Recursion Pharmaceuticals Quarterly Balance Sheet
NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Recursion Pharmaceuticals financial position
As of Jun 30, 2026, Recursion Pharmaceuticals reported total assets of $1.21 billion, down 6.9% from a year earlier against total liabilities of $297.7 million. Shareholders' equity stood at $915.0 million, or 75.5% of assets. The company held $545.7 million in cash and equivalents against $14.2 million of debt, a net cash position of $531.5 million.
The current ratio (current assets divided by current liabilities) was 5.03, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.02.
Summary generated from market data by MetaCap's automated system. Methodology
Recursion Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 545.68M | 654.47M | 743.29M | 659.84M | 525.11M | 500.45M | 594.35M | 427.65M | 474.34M | 296.33M | 391.56M | 387.32M |
| Total Current Assets | 603.46M | 709.56M | 812.85M | 714.11M | 587.16M | 584.14M | 714.27M | 474.17M | 522.38M | 343.62M | 438.14M | 410.52M |
| Property, Plant & Equipment | 89.62M | 95.81M | 103.93M | 111.71M | 120.04M | 126.83M | 141.06M | 84.41M | 83.63M | 86.72M | 86.51M | 86.25M |
| Goodwill | 160.35M | 160.17M | 162.16M | 162.04M | 164.27M | 158.11M | 148.87M | 52.06M | 52.06M | 52.06M | 52.06M | 52.75M |
| Intangible Assets | 282.89M | 294.07M | 309.90M | 322.34M | 341.32M | 335.79M | 335.86M | 34.09M | 38.21M | 33.08M | 36.44M | 39.46M |
| Total Assets | 1.21B | 1.34B | 1.47B | 1.40B | 1.30B | 1.31B | 1.45B | 726.50M | 775.86M | 557.85M | 653.70M | 630.83M |
| Accounts Payable | 12.67M | 20.35M | 18.12M | 13.94M | 19.31M | 25.09M | 21.61M | 2.26M | 3.76M | 5.12M | 3.95M | 4.26M |
| Short-Term Debt | 9.44M | 9.27M | 9.09M | 8.92M | 8.75M | 8.59M | 8.43M | 8.22M | 8.11M | — | 41.00K | — |
| Total Current Liabilities | 119.89M | 129.70M | 147.71M | 155.10M | 164.03M | 141.98M | 187.47M | 108.89M | 86.08M | 73.92M | 93.17M | 94.12M |
| Long-Term Debt | 4.75M | 7.18M | 9.56M | 11.90M | 14.20M | 16.45M | 19.02M | 20.51M | 22.92M | 1.07M | 1.10M | 1.13M |
| Total Liabilities | 297.67M | 314.75M | 343.26M | 352.58M | 383.21M | 371.29M | 413.82M | 201.94M | 191.41M | 156.70M | 190.26M | 192.86M |
| Shareholders' Equity | 915.00M | 1.02B | 1.13B | 1.05B | 919.15M | 933.95M | 1.03B | 524.56M | 584.45M | 401.15M | 463.44M | 437.97M |
| Retained Earnings | -2.32B | -2.19B | -2.08B | -1.97B | -1.81B | -1.63B | -1.43B | -1.25B | -1.16B | -1.06B | -967.62M | -874.63M |
| Total Debt | 14.20M | 16.45M | 18.66M | 20.82M | 22.95M | 25.03M | 27.45M | 28.73M | 31.03M | 1.07M | 1.14M | 1.13M |
| Net Cash (Debt) | 531.49M | 638.03M | 724.64M | 639.01M | 502.16M | 475.42M | 566.90M | 398.92M | 443.31M | 295.25M | 390.42M | 386.20M |
| Shares Outstanding | 534.12M | 530.63M | 528.18M | 491.80M | 432.83M | 406.41M | 396.80M | 286.12M | 280.97M | 237.51M | 234.27M | 216.31M |
This table shows 12 quarterly periods of Recursion Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow RXRX's reporting calendar. What is a balance sheet?